Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922052 | 0.73 | GAA (0.44) | ALDH1A1KDM4ESMN1; SMN2GAAMAPT | |
| SCHEMBL4339606 | 0.73 | MAP4K4 (0.47) | ALDH1A1KDM4ETSHRGAAHPGD | |
| SCHEMBL1920341 | 0.72 | SRC (0.41) | ALDH1A1KDM4ESMN1; SMN2TSHRGAA | |
| SCHEMBL30639225 | 0.69 | TSHR (0.66) | ALDH1A1KDM4ESMN1; SMN2TSHRGAA | |
| SCHEMBL7878088 | 0.69 | TSHR (0.66) | ALDH1A1KDM4ESMN1; SMN2TSHRGAA | |
| SCHEMBL12533872 | 0.69 | MAP2K1 (0.42) | — | |
| SCHEMBL9867870 | 0.68 | ALDH1A1 (0.68) | ALDH1A1KDM4ESMN1; SMN2TSHRLMNA | |
| Fumaric Acid SCHEMBL8051638 | 0.68 | SLC6A2 (0.48) | ALDH1A1KDM4ESMN1; SMN2TSHRGAA | |
| Maleic Acid SCHEMBL8051635 | 0.68 | SLC6A2 (0.48) | ALDH1A1KDM4ESMN1; SMN2TSHRGAA | |
| SCHEMBL25257553 | 0.68 | LMNA (0.55) | ALDH1A1KDM4ESMN1; SMN2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2099796-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | ALDH1A1 1224/4885KDM4E 270/4885SMN1; SMN2 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.